$0.69
+0.02 (+3.40%)
Open$0.68
Previous Close$0.67
Day High$0.70
Day Low$0.67
52W High$5.75
52W Low$0.57
Volume—
Avg Volume152.3K
Market Cap23.89M
P/E Ratio—
EPS$-1.45
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,193.4% upside
Current
$0.69
$0.69
Target
$15.90
$15.90
$11.92
$15.90 avg
$19.90
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.64M | 3.84M | 3.77M |
| Net Income | 720.4K | 800.4K | 930.4K |
| Profit Margin | 19.8% | 20.8% | 24.7% |
| EBITDA | 1.38M | 1.54M | 1.32M |
| Free Cash Flow | 559.4K | 545.0K | 561.2K |
| Rev Growth | +15.7% | +20.7% | +9.8% |
| Debt/Equity | 0.34 | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |